DAM
PGNX

DLD Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

DLD Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-100,000
Closed -$509K – 115
2019
Q4 		$509K Buy
+100,000
New +$529K 0.03% 83

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

DLD Asset Management's PGNX Position: Q1 2020 in Review

DLD Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 100,000 shares — an estimated $509K sold.

DLD Asset Management first reported a position in PGNX in Q4 2019 and held it in 1 quarter. The position peaked at $509K in Q4 2019. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • DLD Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • DLD Asset Management sold 100,000 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $509K.
  • DLD Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2019 and held it in 1 quarter.
  • DLD Asset Management's Progenics Pharmaceuticals Inc position peaked at $509K in Q4 2019.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on DLD Asset Management's 13F filing for Q1 2020, filed 14 May 2020.